Abstract: A catalyst which is capable of specifically cleaving one sugar chain or two or more sugar chains selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C and chondroitin sulfate D; a cleavage agent specific for the sugar chains; a medicament which is used for specifically cleaving the sugar chains in a living body tissue; a method for specifically cleaving the sugar chains; a method for specifically producing the sugar chain having a decreased molecular weight; and production methods for the catalyst, the cleavage agent and the medicament.

Abstract: A 6-O-sulfated N-acetylheparosan in which a primary hydroxyl group of N-acetylglucosamine constituting N-acetylheparosan is sulfated; a hematopoietic stem cell growth auxiliary agent, which has hematopoietic stem cell growth-accelerating activity and comprises the 6-O-sulfated-N-acetylheparosan as an active ingredient; a medium for a hematopoietic stem cell, which comprises the hematopoietic stem cell growth auxiliary agent and an other medium component necessary for culturing the hematopoietic stem cell; a method for culturing a hematopoietic stem cell, which comprises culturing the hematopoietic stem cell in the presence of the hematopoietic stem cell growth auxiliary agent or in the medium for a hematopoietic stem cell; and a method for treating a blood disease, which comprises transplanting a hematopoietic stem cell cultured by the above method to bone marrow of a mammal.

Abstract: A pharmaceutical composition, which contains glycosaminoglycan having at least one sulfate group or a pharmaceutically acceptable salt thereof, and an immunosuppressant.

Abstract: Dermatan sulfate compositions having certain characteristics have been found to have thrombolytic activity. Dermatan sulfate combined with tissue plasminogen activator (t-PA) enhances the thrombolytic activity of t-PA. Antithrombotic compositions containing dermatan sulfates can be used for treating various thrombotic diseases.